Here, we suggest a novel diagnostic algorithm, which is based on biological markers, including CSF, tau‐PET, and perfusion imaging to characterize and differentiate primary and secondary tauopathies, and which would have implications for future clinical diagnosis and for the advancement in clinical trials. Here, MAPT is linked to tauopathy.